Skip to contentL
Lisata Therapeutics, Inc.
L
LSTALisata Therapeutics, Inc. Released Feb 25, 2021, after the close
10-K filed Feb 25, 2021, 56 days after period end · 0000320017-21-000043
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$5.43M-$5.43Mderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR
N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,446,000N/M Operating Cash Flowderived-$5,567,000N/M Free Cash Flowderived-$5,573,000N/M ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end